These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36529260)

  • 1. Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines.
    Heal DJ; Gosden J; Smith SL; Atterwill CK
    Neuropharmacology; 2023 Mar; 225():109375. PubMed ID: 36529260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective.
    Henningfield JE; Ashworth J; Heal DJ; Smith SL
    J Psychopharmacol; 2023 Jan; 37(1):33-44. PubMed ID: 36588452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations in assessing the abuse potential of psychedelics during drug development.
    Calderon SN; Bonson KR; Reissig CJ; Lloyd JM; Galati S; Chiapperino D
    Neuropharmacology; 2023 Feb; 224():109352. PubMed ID: 36455646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promises and perils of psychedelic pharmacology for psychiatry.
    McClure-Begley TD; Roth BL
    Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.
    Canal CE
    Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
    Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
    J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains.
    Varley TF; Carhart-Harris R; Roseman L; Menon DK; Stamatakis EA
    Neuroimage; 2020 Oct; 220():117049. PubMed ID: 32619708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.